CN113166815A - 肠道宏基因组在筛选pd-1抗体阻断剂疗效方面的用途 - Google Patents

肠道宏基因组在筛选pd-1抗体阻断剂疗效方面的用途 Download PDF

Info

Publication number
CN113166815A
CN113166815A CN201980076831.8A CN201980076831A CN113166815A CN 113166815 A CN113166815 A CN 113166815A CN 201980076831 A CN201980076831 A CN 201980076831A CN 113166815 A CN113166815 A CN 113166815A
Authority
CN
China
Prior art keywords
marker
lung cancer
sample
small cell
cell lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980076831.8A
Other languages
English (en)
Inventor
方超
钟焕姿
侯勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BGI Shenzhen Co Ltd
Original Assignee
BGI Shenzhen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BGI Shenzhen Co Ltd filed Critical BGI Shenzhen Co Ltd
Publication of CN113166815A publication Critical patent/CN113166815A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Abstract

本发明公开了肠道宏基因组在预测PD‑1抗体阻断剂对于癌症的治疗效果中的用途以及用于预测PD‑1抗体阻断剂对非小细胞肺癌患者治疗效果的标志物及应用。该标志物包括选自Streptococcussanguinis，Escherichia coli，Clostridium sp.L2‑50，Citrobacter freundii，Pyramidobacter piscolens，及其类似物中的至少一种。

Description

PCT国内申请，说明书已公开。

Claims (33)

  1. PCT国内申请，权利要求书已公开。
CN201980076831.8A 2019-02-22 2019-02-22 肠道宏基因组在筛选pd-1抗体阻断剂疗效方面的用途 Pending CN113166815A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/075825 WO2020168541A1 (zh) 2019-02-22 2019-02-22 肠道宏基因组在筛选pd-1抗体阻断剂疗效方面的用途

Publications (1)

Publication Number Publication Date
CN113166815A true CN113166815A (zh) 2021-07-23

Family

ID=72144870

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980076831.8A Pending CN113166815A (zh) 2019-02-22 2019-02-22 肠道宏基因组在筛选pd-1抗体阻断剂疗效方面的用途

Country Status (2)

Country Link
CN (1) CN113166815A (zh)
WO (1) WO2020168541A1 (zh)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105209919A (zh) * 2013-03-15 2015-12-30 豪夫迈·罗氏有限公司 治疗pd-1和pd-l1相关疾患的生物标志物和方法
EP3012270A1 (en) * 2014-10-23 2016-04-27 Institut Gustave Roussy Products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
US20160303172A1 (en) * 2013-11-21 2016-10-20 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatment
WO2017050855A1 (en) * 2015-09-22 2017-03-30 Institut Gustave Roussy A scoring method for predicting the efficiency of a treatment with anti-pd-1 and/or anti-pd-l1 monoclonal antibodies
CN107988373A (zh) * 2018-01-10 2018-05-04 上海交通大学医学院附属仁济医院 用于预测癌症免疫治疗效果的生物标志物、试剂盒与应用
WO2018084204A1 (ja) * 2016-11-02 2018-05-11 国立大学法人京都大学 Ｐｄ－１シグナル阻害剤による疾患治療における有効性判定マーカー
CN109266766A (zh) * 2018-10-10 2019-01-25 中国人民解放军第三0二医院 肠道微生物作为胆管细胞癌诊断标志物的用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105209919A (zh) * 2013-03-15 2015-12-30 豪夫迈·罗氏有限公司 治疗pd-1和pd-l1相关疾患的生物标志物和方法
US20160303172A1 (en) * 2013-11-21 2016-10-20 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatment
EP3012270A1 (en) * 2014-10-23 2016-04-27 Institut Gustave Roussy Products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
WO2017050855A1 (en) * 2015-09-22 2017-03-30 Institut Gustave Roussy A scoring method for predicting the efficiency of a treatment with anti-pd-1 and/or anti-pd-l1 monoclonal antibodies
WO2018084204A1 (ja) * 2016-11-02 2018-05-11 国立大学法人京都大学 Ｐｄ－１シグナル阻害剤による疾患治療における有効性判定マーカー
CN107988373A (zh) * 2018-01-10 2018-05-04 上海交通大学医学院附属仁济医院 用于预测癌症免疫治疗效果的生物标志物、试剂盒与应用
CN109266766A (zh) * 2018-10-10 2019-01-25 中国人民解放军第三0二医院 肠道微生物作为胆管细胞癌诊断标志物的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KEISHI ADACHI等: "Microbial biomarkers for immune checkpoint blockade therapy against cancer", 《JOURNAL OF GASTROENTEROL》, no. 53, pages 999 - 1005 *
YUKI OWADA-OZAKI等: "A Study of Biomarkers in Immuno-Oncology - Correlation between Gut Microbiome Composition and the Effects of Immune Checkpoint Inhibitors", 《JAPANESE JOURNAL OF CANCER AND CHEMOTHERAPY》, vol. 45, no. 9, pages 1234 - 1237 *

Also Published As

Publication number Publication date
WO2020168541A1 (zh) 2020-08-27

Similar Documents

Publication Publication Date Title
Peng et al. The gut microbiome is associated with clinical response to anti–PD-1/PD-L1 immunotherapy in gastrointestinal cancer
CN105368944B (zh) 可检测疾病的生物标志物及其用途
WO2021184412A1 (zh) 基于肠道微生物的双相情感障碍生物标志物及其筛选应用
CN105296590B (zh) 大肠癌标志物及其应用
CN111440884A (zh) 源于肠道的诊断肌少症的菌群及其用途
CN105132518B (zh) 大肠癌标志物及其应用
CN104540962A (zh) 糖尿病生物标志物及其应用
WO2018223066A1 (en) Methods and systems for identifying or monitoring lung disease
CN110904213B (zh) 一种基于肠道菌群的溃疡性结肠炎生物标志物及其应用
WO2020244018A1 (zh) 一种精神分裂症的小规模生物标志物组合、其应用及metaphlan2筛选方法
WO2016050111A1 (en) Biomarkers for rheumatoid arthritis and usage thereof
WO2019205188A1 (zh) 抑郁症生物标志物及其用途
CN111455074B (zh) 用于评估胰腺癌化疗疗效的微生物菌群标志物及其应用
Li et al. A novel mitochondrial-related gene signature for the tumor immune microenvironment evaluation and prognosis prediction in lung adenocarcinoma
CN111020020A (zh) 一种精神分裂症的生物标志物组合、其应用及metaphlan2筛选方法
CN110396538B (zh) 偏头痛生物标志物及其用途
CN112384634B (zh) 骨质疏松生物标志物及其用途
US20240153588A1 (en) Systems and methods for identifying microbial biosynthetic genetic clusters
CN113166815A (zh) 肠道宏基因组在筛选pd-1抗体阻断剂疗效方面的用途
CN112481380B (zh) 一种评估晚期膀胱癌抗肿瘤免疫治疗反应性和预后生存的标志物及其应用
CN112011605B (zh) 微生物菌群在疾病诊断中的应用
CN112063709A (zh) 一种以微生物作为诊断标志物的重症肌无力的诊断试剂盒及应用
CN111020021A (zh) 一种基于肠道菌群的小规模精神分裂症生物标志物组合、其应用及mOTU筛选方法
JP2011004743A (ja) 関節リウマチ患者におけるインフリキシマブ薬効の有効性を判別する方法
CN110396537B (zh) 哮喘生物标志物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40048536

Country of ref document: HK